Aportamos los resultados preliminares del tratamiento en 33 pacientes con adenitis tuberculosa periférica, con un esquema de nueve meses que incluía: rifampicina 600mg/día e isoniacida 300mg/día, más etambutol 25mg/kg/dia los dos primeros meses.
Durante el tratamiento, a partir del tercer mes, dos casos precisaron drenaje quirúrgico, uno desbridamiento de un absceso y otro exéresis quirúrgica. Al final del tratamiento los otros 27 casos habían evolucionado satisfactoriamente y no precisaron cirugía. No se presentaron complicaciones clínicas secundarias a la quimioterapia.
De los 33 pacientes, en 24 ha transcurrido más de un año desde que finalizaron el tratamiento. Uno de ellos no ha acudido a control, los 23 restantes se presentaron al año de terminar la terapéutica y en ninguno de ellos ha habido recidivas.
Con estos resultados pensamos que, al igual que en la tuberculosis pulmonar, la adenitis tuberculosa periférica puede ser tratada con prácticamente el 100% de curaciones con esquemas de nueve meses que incluyan rifampicina e isoniacida.
The authors present the preliminary results of a ninemonth treatment for peripheral tuberculous adenitis.
The trial included 33 patients who were given rifampicin at doses of 600mg/day and isoniazid at doses of 300mg/day plus 25mg/Kg/day ethambutol for the first two months.
After the third month of treatment two patients required surgical drainage and debridement of an abscess and further exeresis. The other 27 patients had a satisfactory response to the therapy and did not require surgical treatment. No side effects to the chemotherapy were seen in any of the patients.
Of the 24 patients out of the total 33 in the group, for whom more than one year has elapsed since finishing therapy, 23 were seen exactly one year later while one was lost to followup; there were no relapses.
These results strongly suggest that peripherical tuberculous adenitis may be treated succesfully —as in pulmonary tuberculosis— with a nine month schedule including rifampicin and isoniazids which elicit a cure rate of approximately 100%.
